Cue Biopharma (CUE) Net Margin (2018 - 2025)

Cue Biopharma has disclosed Net Margin across 8 years of filings, most recently posting 244.28% for Q4 2025.

• Net Margin for Q4 2025 came in at 244.28%, down 125419.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 31.5% (up 4299.0% YoY), and the FY2025 annual result was 18.84%, up 5566.0% from the prior year.
• Net Margin came in at 244.28% for Q4 2025 at Cue Biopharma, up from 343.09% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1498.48% in Q4 2024 to a low of 50800.0% in Q2 2022.
• The 5-year median for Net Margin is 623.79% (2021), against an average of 4582.56%.
• Across the five-year window, Net Margin sank 5042472 bps in 2022 and surged 4986274 bps in 2023, its largest moves.
• Cue Biopharma's Net Margin stood at 95.58% in 2021, then tumbled by 9763 bps to 9426.49% in 2022, then jumped by 92 bps to 709.88% in 2023, then surged by 311 bps to 1498.48% in 2024, then plunged by 84 bps to 244.28% in 2025.
• The last three Net Margin figures came in at 244.28% (Q4 2025), 343.09% (Q3 2025), and 285.61% (Q2 2025), per Business Quant data.